CHF Solutions Continues Physician-Led Webinar Series Discussing Precise Management of Fluid Overload in Patients with Acute H...
September 03 2020 - 08:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced the company will host an interactive, physician-led
webinar to discuss “Precision Medicine for the Treatment of Fluid
Overload in Patients with Acute Heart Failure.” The virtual event
will be led by Dr. John L. Jefferies, the Jay M. Sullivan
Distinguished Chair in Cardiovascular Medicine and Chief of
Cardiology at the University of Tennessee Health Science Center,
and will take place on Tuesday, Sept. 8 at 3 p.m. Eastern Time.
Ninety percent of the nearly one million annual heart failure
hospitalizations in the U.S. are due to signs and symptoms of fluid
overload. Heart failure patients are also frequently readmitted,
with nearly twenty-five percent being rehospitalized within thirty
days. Today, diuretics are the first line of treatment in the
management of fluid overload; however, they are associated with
mixed outcomes and dangerous complications.1 Dr. Jefferies will
discuss alternative fluid management treatment options, such as
ultrafiltration using AquadexTM .
“Millions of Americans suffer from heart failure, and the more
treatment options providers can understand and utilize, the better
care we can provide for patients,” said Dr. Jefferies. “Fluid
overload is an underrecognized component to heart failure.
Precisely managing volume overload in heart failure patients is a
critical step in ensuring positive outcomes.”
“We appreciate Dr. Jefferies sharing his deep clinical
experience in treating heart failure patients and we’ll continue to
support educational opportunities for the medical community helping
these patients every day,” said John L. Erb, CEO of CHF
Solutions.
Dr. Jefferies serves as Director of the Methodist University of
Tennessee Cardiovascular Institute. He is a Professor of Pediatric
Cardiology, Professor of Preventive Medicine, and a Research Member
of St. Jude Children’s Research Hospital. Dr. Jefferies has
published 200 peer-reviewed manuscripts and is the Lead Editor for
two widely acclaimed textbooks.
Register to participate in this informative webinar by following
this link:
https://zoom.us/webinar/register/WN_TtoDtKcYTr-VUJwz5-WJcg. For
those unable to attend the webinar, an archive of the webcast will
be available at http://ir.chf-solutions.com/events and
https://www.youtube.com/channel/UCNMGN9ujo1NduyGSca7hwZw
within 48 hours after the event concludes.
1. Constanzo MR, et. al. J Am Coll Cardiol. 2017;
69(19)2428-2445.
About CHF Solutions
CHF Solutions, Inc. (CHFS) is a medical device company dedicated
to changing the lives of patients suffering from fluid overload
through science, collaboration, and innovation. The company is
focused on developing, manufacturing and commercializing the
Aquadex SmartFlow™ system for ultrafiltration therapy. CHF
Solutions is headquartered in Minneapolis, Minn., with wholly-owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy
using a simple, flexible and smart method of removing excess fluid
from patients suffering from hypervolemia (fluid overload). The
Aquadex SmartFlow system is indicated for temporary (up to 8 hours)
or extended (longer than 8 hours in patients who require
hospitalization) use in adult and pediatric patients weighing 20 kg
or more whose fluid overload is unresponsive to medical management,
including diuretics. All treatments must be administered by a
health care provider, within an outpatient or inpatient clinical
setting, under physician prescription, both having received
training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements about the treatment of fluid overload in
patients with acute heart failure. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our expectations regarding
the potential impacts of the COVID-19 pandemic on our business
operations, our ability to execute on our commercial strategy, the
possibility that we may be unable to raise sufficient funds
necessary for our anticipated operations, our post-market clinical
data collection activities, benefits of our products to patients,
our expectations with respect to product development and
commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive
product offerings, intellectual property protection, our ability to
integrate acquired businesses, our expectations regarding
anticipated synergies with and benefits from acquired businesses,
and other risks and uncertainties described in our filings with the
SEC. Forward-looking statements speak only as of the date when
made. CHF Solutions does not assume any obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Feb 2024 to Mar 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2023 to Mar 2024